



HAL
open science

Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion

A Martín, Robert Benamouzig, Isabelle Guoin-Thibault, Jeannot Schmidt

► To cite this version:

A Martín, Robert Benamouzig, Isabelle Guoin-Thibault, Jeannot Schmidt. Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion. *American Journal of Cardiovascular Drugs*, In press, 10.1007/s40256-023-00582-9 . hal-04100003

HAL Id: hal-04100003

<https://hal.science/hal-04100003>

Submitted on 17 May 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License



Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion

Anne-Céline Martin^{1,2} · Robert Benamouzig³ · Isabelle Gouin-Thibault⁴ · Jeannot Schmidt^{5,6}

Accepted: 5 April 2023
© The Author(s) 2023

Abstract

Direct oral anticoagulants (DOACs) are recommended for the prevention of thromboembolism in patients with atrial fibrillation (AF), and are now preferred over vitamin K antagonists due to their beneficial efficacy and safety profile. However, all oral anticoagulants carry a risk of gastrointestinal (GI) bleeding. Although the risk is well documented and acute bleeding well codified, there is limited high-quality evidence and no guidelines to guide physicians on the optimal management of anticoagulation after a GI bleeding event. The aim of this review is to provide a multidisciplinary critical discussion of the optimal management of GI bleeding in patients with AF receiving oral anticoagulants to help physicians provide individualized treatment for each patient and optimize outcomes. It is important to perform endoscopy when a patient presents with bleeding manifestations or hemodynamic instability to determine the bleed location and severity of bleeding and then perform initial resuscitation. Administration of all anticoagulants and antiplatelets should be stopped and bleeding allowed to resolve with time; however, anticoagulant reversal should be considered for patients who have life-threatening bleeding or when the bleeding is not controlled by the initial resuscitation. Anticoagulation needs to be timely resumed considering that bleeding risk outweighs thrombotic risk when anticoagulation is resumed early after the bleeding event. To prevent further bleeding, physicians should prescribe anticoagulant therapy with the lowest risk of GI bleeding, avoid medications with GI toxicity, and consider the effect of concomitant medications on potentiating the bleeding risk.

Key Points

While oral anticoagulants are recommended for the prevention of thromboembolism in patients with atrial fibrillation (AF), a major complication of their use is an increased risk of bleeding, including gastrointestinal (GI) bleeding.

Severe GI bleeding is associated with poor prognosis; however, reintroduction of oral anticoagulants after GI bleeding management is associated with increased survival rates.

The optimal management of GI bleeding in patients receiving anticoagulants relies on multidisciplinary care, including gastroenterologists and cardiologists, as well as intensivists and hemostasis specialists in particular cases, to provide an individualized optimal balance of benefit and risk.

✉ Anne-Céline Martin
anne-celine.martin@aphp.fr

¹ Advanced Heart Failure Unit, AP-HP, Cardiology Department, European Hospital Georges Pompidou, Paris, France

² INSERM UMRS_1140, Innovative Therapies in Haemostasis, Université Paris Cité, 75006 Paris, France

³ Service de Gastroentérologie, Hôpital Avicenne, AP-HP, Université Paris-Nord-La Sorbonne, Bobigny, France

⁴ Laboratory of Hematology, IRSET-INSERM UMRS 1085, Rennes University Hospital, Rennes, France

⁵ LaPSCo, Physiological and Psychosocial Stress, CNRS, Université Clermont Auvergne, Clermont-Ferrand, France

⁶ Emergency Department, CHU Clermont-Ferrand, University Hospital Gabriel Montpied, Clermont-Ferrand, France

1 Introduction

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia that increases the risk of cardiovascular events such as stroke, systemic embolism, and heart failure and promotes the worsening of cardiac and noncardiac conditions [1, 2]. According to the Global Burden of Disease Study, there were 37.57 million [95% uncertainty interval (UI) 32.55–42.59] prevalent cases of AF and 3.05 million (95% UI 2.61–3.51) incident cases of AF worldwide in 2017 [2]. The prevalence of AF has nearly doubled between 1990 and 2017, and rates are expected to keep increasing due to the aging population [2].

European guidelines recommend the use of direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, apixaban, or edoxaban for the prevention of stroke and systemic embolism in AF [3, 4]. Their mechanism of action is based on the direct inhibition of activated coagulation factors; dabigatran inhibits thrombin (factor IIa), while rivaroxaban, apixaban, and edoxaban inhibit factor Xa [5–10]. Overall, DOACs are preferred over vitamin K antagonists (VKA) such as warfarin in adult patients, except in the context of pregnancy and in patients with mechanical valve prosthesis, triple-positive antiphospholipid syndrome, or end-stage kidney disease [3, 11]. DOACs are being increasingly used due to their improved efficacy/safety ratio, predictable anticoagulant effect without need for routine coagulation monitoring, fixed dose regimens, and fewer food and drug interactions compared with VKAs [12]. However, gastrointestinal (GI) bleeding remains a serious and challenging complication of any anticoagulant medication [13]. The management of acute major bleeding in patients treated with anticoagulants is well codified [14], but there is a lack of standardized protocols as to how and when to resume anticoagulant therapy after GI bleeding. As such, international guidelines recommend the development of a hospital-based multidisciplinary approach including cardiologists, gastroenterologists, emergency physicians/intensive care specialists, hemostasis experts, and others to optimally treat patients with GI bleeding [3].

This article aims to critically discuss the optimal approach to the multidisciplinary management of GI bleeding in patients with AF receiving anticoagulants.

2 Risk of GI Bleeding Depending on the Type of Oral Anticoagulant

All anticoagulants may promote or potentiate bleeding from a preexisting GI lesion. Although the pathophysiology remains unclear [15], several mechanisms by which

anticoagulant agents may contribute to GI bleeding have been suggested [16]. For example, warfarin has been associated with GI bleeding via a systemic decrease in vitamin-K-dependent clotting factors; because warfarin is not directly active, 95% of a dose is absorbed in the GI tract and the unabsorbed 5% does not have anticoagulant activity [13, 17, 18]. In contrast, factor Xa inhibitors are directly active and are not completely absorbed, so the unabsorbed drug may have a direct topical effect on GI tissues, potentially increasing the risk of bleeding [17]. The dabigatran prodrug has only 6% oral bioavailability, and the unabsorbed prodrug could be activated intraluminally during transit through the GI tract. Factor Xa inhibitors have higher (50–80%) oral bioavailability than dabigatran [19] and are reported to have different GI bleeding safety profiles. It is also possible that anticoagulants induce bleeding by compromising GI mucosal integrity and/or inhibiting its healing [17, 20].

The comparative bleeding risk of VKAs (warfarin) and DOACs in patients with AF has been evaluated in several clinical trials. In the RE-LY trial, the risk of major GI bleeding with dabigatran was dose dependent, and only higher doses of dabigatran [150 mg twice daily (BID) but not 110 mg BID] increased bleeding risk compared with warfarin [1.51% versus 1.02% per year, respectively; relative risk (RR) 1.50; 95% confidence interval (CI) 1.19–1.89; $p < 0.001$] [21]. Similarly, in the ENGAGE AF-TIMI 48 trial, edoxaban doses of 60 mg once daily (QD) but not 30 mg QD significantly increased GI major bleeding risk in patients versus warfarin [60 mg QD of edoxaban, 1.51% versus warfarin, 1.23% per year; hazard ratio (HR) 1.23; 95% CI 1.02–1.50 per year; $p = 0.03$; and 30 mg QD of edoxaban, 0.82% versus warfarin, 1.23%; HR 0.67; 95% CI 0.53–0.83; $p < 0.001$] [22]. The ROCKET AF trial showed that major GI bleeding was significantly higher in patients treated with 20 mg rivaroxaban QD compared with warfarin (2.00% versus 1.24% per year, respectively; HR 1.66; 95% CI 1.34–2.05; $p < 0.0001$) [23]. Similar rates of major GI bleeding were found in the ARISTOTLE trial between 5 mg apixaban BID and warfarin (0.76% versus 0.86% per year, respectively; HR 0.89; 95% CI 0.70–1.15; $p = 0.37$) [24]. In the absence of direct head-to-head comparisons between DOACs, no conclusions can be drawn regarding which drug has the lowest GI bleeding risk [25]. Differences between DOACs could be due to differences in dosage, reporting of GI bleeding, or the study population (e.g., compared with the RE-LY and ARISTOTLE trial populations, the ROCKET-AF trial population was older and had more comorbidities at baseline) [21, 23, 24]. Whether the different chemical structures and differences in the pharmacodynamic and pharmacokinetic characteristics have an impact on the GI bleeding risk between DOACs is still unknown [16, 26].

3 Clinical Factors that Predict Bleeding and Poor Prognosis in Anticoagulant-Treated Patients

Advanced age, intestinal ischemia, multiple comorbidities, blood cell transfusion, and in-hospital bleeding in the lower GI tract have been reported as risk factors for in-hospital mortality, post-discharge mortality, and 30-day hospital readmissions [27]. Hypertension [systolic blood pressure (SBP) > 160 mmHg], stroke, low hemoglobin (< 13 g/dL in men and < 12 g/dL in women), coexisting hepatic or renal diseases, and concomitant use of medications that affect hemostasis (e.g., antiplatelet therapy) increase morbidity and worsen outcomes in patients treated with anticoagulants [28].

The GI bleeding risk with DOACs depends on the dosage and type of DOAC used, on patient characteristics [ethnicity, older age (> 75 years), and comorbidities such as chronic kidney disease (CKD) and cirrhosis], and on concomitant use of other medications such as proton pump inhibitors (PPIs) or histamine H₂-receptor antagonists [13, 29, 30]. Acute coronary syndrome has also been related to an increased risk of GI bleeding [odds ratio (OR) 5.21] in patients treated with DOACs, especially those who are co-prescribed antiplatelet agents [13]. Another risk factor for DOAC-related GI bleeding is renal impairment. AF affects about 18% of patients with CKD and > 25% of patients with CKD older than 70 years [31]; compared with the general population, patients with CKD receiving DOACs have an increased risk of thromboembolism and bleeding due to altered pharmacokinetics, decreased clearance, and altered volume of distribution because of reduced kidney function and limited protein binding [32]. However, the benefit–risk profile of DOACs has been reported to be superior to that of VKAs in the early stages of CKD [32, 33]. Patients with cirrhosis are also at an increased risk of bleeding compared with the general population. No DOACs are recommended in Child–Pugh score C. In Child–Pugh score B, rivaroxaban is not recommended, while dabigatran, apixaban, and edoxaban should be used with caution [3]; however, more data are needed to evaluate how cirrhosis increases the bleeding risk in patients treated with DOACs [34].

Elderly patients present a particular challenge because of coexisting comorbidities, frailty, and concomitant medications increasing the risk of drug interactions [35]. A study comparing the risk of GI bleeding with dabigatran, rivaroxaban, or apixaban in patients with AF showed that rates of events for all DOACs increased among patients 75 years or older. However, apixaban had a lower risk of association with GI bleeding in the very elderly than dabigatran or rivaroxaban [36].

Several scores have been described to assess bleeding risk, especially in patients with AF exposed to long-term anticoagulation therapy. The HAS-BLED scale identifies patients at higher risk of bleeding by assessing the following risk factors: hypertension (SBP > 160 mmHg), abnormal renal and/or liver function, history of stroke or thromboembolism, history of bleeding or bleeding diathesis (severe anemia), age > 65 years, use of aspirin or nonsteroidal antiinflammatory drugs, and alcohol abuse [37]. The use of this tool may help to design individualized anticoagulant therapy on the basis of patient characteristics, especially in patients with an elevated bleeding risk [28]. In a systematic review commissioned by the PCORI including 38 studies on bleeding risk prediction, the HAS-BLED score had the best evidence for predicting bleeding risk [38]. However, this score and other bleeding scores (i.e., ATRIA) yielded only moderate discrimination ($c = 0.60$, 95% CI 0.59–0.62 for the HAS-BLED score and $c = 0.63$, 95% CI 0.61–0.65 for the ATRIA bleeding risk score in the ORBIT-AR Registry) and should be critically used [39].

4 Key Steps to Triage Patients on Active Anticoagulant Treatment and GI Bleeding in the Emergency Department

When a patient enters the emergency department with a suspected clinically relevant GI bleed, it is important to evaluate the patient's medical history, dosage, and timing of last DOAC intake [13], concomitant medications, and presenting/underlying conditions along with severity, location, and potential source of the bleeding [40] (Table 1, Fig. 1). Additionally, vital signs such as blood pressure, temperature, and cardiac and respiratory frequency as well as the status of hemorrhagic shock should be assessed [41, 42], and history of prior digestive system bleeding episodes should be investigated [42]. Possible bleeding locations other than the GI tract should be excluded [43]. Simultaneously, hemodynamic and cardiorespiratory stabilization must be performed. Resuscitation measures must be applied according to the Airway, Breathing, Circulation, Disability, Exposure (ABCDE) approach. Additionally, consider oxygen supplementation and orotracheal intubation to protect the patient's airway in case of persistent hematemesis or change in consciousness level [42, 44]. Oxygen supplementation should be administered with caution due to the potential release of free oxygen radicals that may negatively impact myocardium and cardiac function [45]. One of the immediate priorities in a patient with GI bleeding is to establish intravenous (IV) access in order to provide volume resuscitation. The European Society of Gastrointestinal Endoscopy recommends a restrictive red blood cell (RBC) transfusion with a target hemoglobin level between 7 and 9 g/dL; a higher target

Table 1. Multidisciplinary guidelines for resuming DOACs in a patient with upper gastrointestinal bleeding, considering endoscopic parameters and thromboembolic risk

	Low risk of thrombosis CHA_2DS_2 -VASc score 0–1	High risk of thrombosis CHA_2DS_2 -VASc score ≥ 2 or >3
Low risk of bleeding Forrest ulcer > 2, OV with no red sign Endoscopic procedure with low risk of bleeding	Rethink the need for DOACs?	Stop DOACs for 1–3 days and restart once stabilized
High risk of bleeding Forrest 1 or 2 ulcer, OV with red sign Endoscopic procedure with high risk of bleeding	Rethink the need for DOACs and, if necessary, restart after a 3-day break	Stop DOACs for 3 days and restart once stabilized with endoscopic control If possible, delay the endoscopic procedure

CHA_2DS_2 -VASc congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack (TIA), vascular disease, age 65–74 years, sex category, *DOAC* direct oral anticoagulants, *OV* esophageal varices.

Physical assessment		Medication history	Laboratory data	Bleeding location
Presentation	Vital signs	<ul style="list-style-type: none"> • DOAC type and dose • time since last DOAC intake • concomitant drugs 	<ul style="list-style-type: none"> • DOAC concentration • blood count • serum creatinine • liver function • blood group 	<ul style="list-style-type: none"> • Upper GI • Lower GI • other <ul style="list-style-type: none"> - haemoptysis - posterior epistaxis - vomiting of swallowed blood
<ul style="list-style-type: none"> • melena • dizziness • syncope 	<ul style="list-style-type: none"> • blood pressure • heart rate • shock index • respiratory rate • oxygen saturation • body temperature • blood sugar level • ECG 			

Fig. 1 Parameters to consider in the management of a patient at the emergency department with suspected clinically relevant GI bleeding. *DOAC* direct oral anticoagulant, *ECG* electrocardiogram, *GI* gastrointestinal, *INR* international normalized ratio

hemoglobin should be considered in patients with significant comorbidity, such as a history of myocardial infarction [42]. Several scales have been developed to define bleeding severity, including the Thrombolysis in Myocardial Infarction (TIMI), Global Usage of Strategies to Open Occluded Arteries (GUSTO), and Bleeding Academic Research Consortium (BARC) scales, and these are widely used in clinical trials.

The International Society on Thrombosis and Hemostasis (ISTH) defines major bleeding as symptomatic bleeding in a critical organ or area, and/or causing a ≥ 20 g/L fall in hemoglobin or requiring a transfusion of ≥ 2 units of whole

blood or red cells [46, 47]. In addition to these parameters, the American College of Cardiology includes hemodynamic instability [increased heart rate, SBP < 90 mmHg, decrease in SBP > 40 mmHg, or orthostatic blood pressure changes, SBP drop of ≥ 20 mmHg or diastolic blood pressure (DBP) drop of ≥ 10 mmHg upon standing] [14]. The Haute Autorité de Santé (HAS) defines severe bleeding as bleeding that requires urgent and specific management; any other bleeding situation is classified as nonsevere. Severe bleeding events are those that are accompanied by one or more of the following criteria: externalized bleeding that cannot be stopped by application of conventional methods,

hemodynamic instability (SBP < 90 mmHg or \geq 40 mmHg lower than usual, or mean arterial pressure < 65 mmHg, or signs of shock), need for an emergency procedure to stop the bleeding (e.g., endoscopy, interventional radiology, or surgery), need for packed RBC transfusion, and bleeding that is life-threatening or compromises function (including acute GI bleeding) [48, 49].

In patients with upper GI hemorrhage, the Glasgow-Blatchford score (GBS) has been useful for stratifying the risk of needing treatment to manage bleeding in patients treated with anticoagulants and includes the following parameters: hemoglobin and blood urea nitrogen levels, initial SBP, heart rate, presence of melena or syncope, and presence of heart failure or hepatic disease [50]. If a peptic ulcer is the likely cause of upper GI bleeding, IV PPIs (e.g., omeprazole bolus of 80 mg then 8 mg/h infusion) may be administered for 72 h, followed by early transition to oral PPI therapy. The platelet plug is best stabilized if the gastric pH is greater than 5.4, that can be achieved with various PPIs infusion regimen or an oral route when possible. In patients with cirrhosis, esophageal varices are the likely source of bleeding, and these patients should receive somatostatin analogs (e.g., octreotide) and antibiotics (e.g., ceftriaxone or fluoroquinolones) [51]. Somatostatin infusion decreases arterial blood flow to the stomach and duodenum and portal blood flow. Prophylactic antibiotherapy decreases infection, infection mortality rate and all-cause mortality in cirrhotic patients with gastrointestinal bleeding.

An upper endoscopy should be performed if a patient presents with melena, hematemesis, or hematochezia or hemodynamic instability (signs of hypovolemia and iron-deficiency anemia) to allow for the determination of bleeding cause and location [41, 52].

5 Role of Endoscopy in the Assessment and Management of Patients with GI Bleeding

It is often challenging to distinguish between upper and lower GI bleeding on the basis of initial symptoms. Endoscopies aid in determining the location and cause of bleeding to optimize patient management, stop bleeding, and prevent recurrence [53]. Physicians may consider administration of IV erythromycin before endoscopy, with ECG assessment of the QT interval and careful monitoring of potential arrhythmia in patients with cardiovascular disease or taking antiarrhythmic drugs. No alternative drug with such a prokinetic effect is currently available. Glycoprotein (P-gp) and CYP3A4/5 inhibitors such as erythromycin interact with DOACs [53–56], resulting in an increase in DOAC plasma concentration, which can potentially worsen or prolong bleeding events [57].

In emergency situations, the recommended timing of the endoscopy varies depending on whether the patient is suspected of having an upper or lower GI bleeding event, and it also differs between guidelines [52]. Different scores can be used in this scenario; the GBS is often used to determine the need for endoscopic treatment and transfusion, and to predict re-bleeding rate and prognosis [50]. This score has been validated as a predictive tool of in-hospital mortality and therapeutic endoscopic need, even prior to the identification of the bleeding source [58]. Patients with a GBS of 0 are considered to be at low risk and can be managed conservatively without the need for endoscopic investigation. The Forrest classification is used to categorize endoscopy findings such as active bleeding (Forrest Ia), high-risk lesion (Forrest Ib–IIc), and low-risk lesions without signs of active bleeding or recent hemorrhage (Forrest III) [59].

The Forrest classification can also be helpful for assessing the probability of bleeding recurrence, and can be used with other risk scores to weigh the benefit/risk of resuming anticoagulation [60]. The Rockall score system predicts the likelihood of death within 30 days by using patient age; accompanying shock; comorbidities such as heart, liver, and kidney disease; causative diseases of bleeding; and endoscopic bleeding stigmata [61]. It has been validated and is recommended by international guidelines [62].

Patients with suspected lower GI bleeding may require a colonoscopy to locate the bleeding site [51], for which bowel preparation is recommended [52]. Colonoscopies can detect diverticular bleeding or angiodysplastic bleeding [63]. Endoscopic methods of hemostasis for acute upper or lower GI bleeding include injection (usually diluted epinephrine or a special sclerosing agent), contact and non-contact thermal devices (unipolar or bipolar electrocoagulation, heater probes, and argon plasma coagulation), and mechanical devices (endoscopic clips and band ligation) [64, 65]. Patients who have had these procedures may undergo a repeat endoscopy 24 h later.

6 Use of Reversal Agents in Patients with GI Bleeding

Anticoagulants and antiplatelets should be stopped on admission in patients with GI bleeding. The pharmacokinetic profile (half-life) of DOACs makes time the best antidote for bleeding in most situations. However, physicians should consider anticoagulant reversal in patients who have life-threatening bleeding or when the bleeding is not controlled by the initial resuscitation methods described above [66]. For VKA antagonization, prothrombin complex concentrate (PCC) 25 IU/kg is recommended. DOAC reversal is indicated for a concentration over 50 ng/mL. Below this

threshold, bleeding is not considered to be related to DOACs [67].

The US Food and Drug Administration and the European Medicines Agency approved idarucizumab as a specific reversal agent for dabigatran in 2015. Idarucizumab is a humanized monoclonal antibody fragment that can be used for the emergency reversal of dabigatran's anticoagulant effect [68–71]. However, prohemostatic agents, namely PCC or activated PCC (aPCC) 30–50 U/kg IV, can be administered if a specific antidote is not available. Few data support the use of oral activated charcoal within 6 h of drug intake, especially in the context of overdose [66]. Regarding factor Xa inhibitors, the US Food and Drug Administration approved andexanet alfa for the reversal of apixaban and rivaroxaban in life-threatening or uncontrolled bleeding under its accelerated approval program in 2018 [72]. The approval was conditional on performance of an ongoing randomized clinical trial (ANNEXA-I NCT03661528). The European Medicines Agency also gave conditional approval in April 2019, and full marketing approval was granted in Japan in March 2022, including for the reversal of edoxaban in patients with life-threatening or uncontrolled bleeding. Andexanet alfa is a recombinant inactive form of factor Xa that binds to the factor Xa inhibitors. Andexanet alfa is administered as a bolus followed by a continuous infusion, with the dosage dependent on the DOAC dose and the time of last drug intake [72]. PCC 50 IU/kg or aPCC 30–50 IU/kg are recommended if a specific antidote is not available. A recent observational study suggested that aPCC (25 IU/kg or 50 IU/kg for intracerebral hemorrhage or 30 IU/kg for GI bleeding) could be an option in patients with life-threatening bleeding associated with apixaban or rivaroxaban. Indeed, a clinical hemostasis was achieved in 24/35 patients, including 10/10 patients with GI bleeding after aPCC administration [73].

However, given the methodological limitations of open-label single-cohort and observational studies, the contribution of idarucizumab, andexanet alfa, PCC, or aPCC to promoting and maintaining hemostasis in case of life-threatening bleeding remains uncertain. In the absence of a control group, it is unclear whether DOAC reversion leads to improved clinical outcomes and whether use of specific antidotes provides more efficacy and safety than prohemostatic agents; all the more so as most GI bleeding can be managed through drug clearance (i.e., short half-life) and maximum supportive measures (e.g., transfusion, procedural/surgical intervention).

7 Timing for Resuming Anticoagulant Therapy after GI Bleeding

The decision to resume anticoagulant therapy after a bleeding event is critically important and should balance the risk of re-bleeding in the case of resumption, and the risk of

thromboembolism if anticoagulation is not resumed. This decision needs to be made on a case-by-case basis after thorough assessment of the risks and benefits [74] by a multidisciplinary team including a gastroenterologist, a cardiologist, and others if needed [3].

Because of the overlap in risk factors for bleeding and thrombotic events, patients who are suffering from anticoagulation-induced bleeding are also at higher risk of thrombotic events. Discontinuation of anticoagulation, a prothrombotic inflammatory response to bleeding, and RBC transfusions may lead to increased rates of thrombotic events. Clearly, balancing the risks of further bleeding versus potentially fatal thrombotic events is critical for decisions about if and when to resume antithrombotic therapy after bleeding.

Resuming treatment was associated with an overall positive effect on the clinical course of patients with AF after the occurrence of a major bleeding event compared with not resuming oral anticoagulants [75]. A systematic review and meta-analysis on the risk of resuming oral anticoagulants after an episode of GI bleeding concluded that resuming treatment seemed to be associated with a reduced risk of thromboembolism (70%) and mortality 235 (49%) despite an increased risk of recurrent GI bleeding (91%) [76]. Another systematic review and meta-analysis using data from > 5000 patients showed similar recurrent GI bleeding risk, and significantly reduced risks of any thromboembolic event in patients resuming oral anticoagulant therapy compared with those who did not. The mortality rate in patients who resumed anticoagulation (21.3%) was lower compared with patients who discontinued anticoagulation (31%), with a significantly lower risk of all-cause mortality (OR 0.499; 95% CI 0.419–0.595; $p < 0.0001$) associated with the resumption of anticoagulation [77]. However, several biases and confounding hinder the interpretation of these two meta-analyses. All the studies included were observational rather than randomized control trials, there was a substantial amount of heterogeneity among them, the timing of anticoagulant resumption varied widely, and outcomes were not reported on the basis of when anticoagulant was resumed. Kido and colleagues have shown a decreased risk of mortality and thromboembolic events without an increased risk of a recurrent GI bleeding event when resuming warfarin within 7–15 days of a GI bleed [78]. A prospective cohort study by Sengupta and colleagues and two review articles by Witt and Radaelly and colleagues, respectively, on the benefit/risk associated with resuming anticoagulation after a GI bleed recommended resuming anticoagulation therapy after no more than 2 weeks to reduce the risk of bleeding, thromboembolism, and mortality [75, 79, 80].

Currently, there are no tools designed to specifically assess the risk of bleeding recurrence at anticoagulation

resumption and to assess whether the risk of re-bleeding is higher than the risk of thrombosis.

Anticoagulation needs to be resumed in a timely manner, bearing in mind that bleeding risk outweighs thrombotic risk when anticoagulation is resumed early after the bleeding event [3]. This is well illustrated in the perioperative setting, where resuming anticoagulation early postoperatively increases the risk of bleeding since it compromises hemostasis [81].

However, the specific time when to resume anticoagulation is not well defined. Majeed et al. demonstrated that bleeding risk decreases over time after a GI bleeding event, especially after 21 days, whereas the risk of thromboembolism is stable over time and is often lower than the bleeding risk [82]. Data suggest that there is a threefold increase in the risk of bleeding if anticoagulation is resumed within 7 days of a hemorrhage compared with after 7 days, but there is no difference in the risk of bleeding if anticoagulants are resumed within 21 days versus after 21 days [82–84]. In the ARISTOTLE trial, resumption occurred at a median time of 15 days [85]. Similarly, in the REVERSE trial, 66% of the patients who had experienced a bleed resumed anticoagulation within 16 days [86].

The former version of the European Heart Rhythm Association (EHRA) guidelines on anticoagulants in patients with AF based the decision-making process on the assessment of factors that favor withholding anticoagulation (such as an unidentifiable site of bleeding, multiple angiodysplasia in the GI tract, no identifiable treatable cause, and older age) and those that favor resuming anticoagulation. The recommendation was to resume DOACs within 4–7 days following

a major GI bleed but only if clinical benefits outweighed the risk of developing recurrent GI bleeding [87].

In the latest version of their guidelines, the EHRA changed their point of view, with the decision-making process suggesting a net assessment in favor of resuming anticoagulation and a recommendation to resume DOACs as early as clinically feasible (Fig. 2) [3].


The American College of Cardiology guidelines recommend determining the optimal timing for oral anticoagulant resumption on the basis of whether there is a greater risk of thromboembolism or bleeding. In conditions with high thrombotic risk, the recommendation is for early resumption of anticoagulation once hemostasis is achieved and the patient is clinically stable; for patients with moderate or high re-bleeding risk, individualized strategies are more appropriate [14].

Further studies and randomized controlled trials are urgently needed to establish optimal timing of DOAC resumption in patients after a GI hemorrhage according to baseline patient characteristics (age, comorbidities, indication for anticoagulants, source and severity of bleeding, risk of re-bleeding or thrombosis).

8 Minimizing the Risk of Recurrences in Patients Resuming Anticoagulants after GI Bleeding

As previously described, resuming anticoagulant treatment after a GI bleeding event generally provides clinical benefit. To prevent recurrent bleeding after a GI bleeding episode,

Fig. 2 Algorithm for the resumption of direct oral anticoagulants after a gastrointestinal hemorrhage according to the European Heart Rhythm Association guidelines [3]. *GI* gastrointestinal, *LAA* left atrial appendage, *NOAC* novel oral anticoagulants. Reproduced from Steffel et al. [3] by permission of Oxford University Press



it is important to evaluate the main risk factors favoring the occurrence of GI bleeding [88], such as the presence of a digestive luminal disease, older age, renal or liver dysfunction, hypertension, anemia, history of hemorrhage or stroke, genetic factors, malignancy, and concomitant treatments and diseases [11, 28, 30, 74]. Overall, despite a potential 23% increase in GI bleeding, DOACs have a 14% trend toward a relative risk reduction in major bleeding relative to warfarin [89]. Since the risk of bleeding appears to be higher with VKAs than with DOACs, it may be advisable to resume with a DOAC after a significant GI bleed.

However, several retrospective cohort studies of real-world patients starting DOAC therapy for AF have shown that, after adjustment for potential confounders, apixaban was associated with a significantly lower risk of major bleeding and GI bleeding compared with rivaroxaban or dabigatran [90–92].

Guidelines stress the need to minimize bleeding risk for all patients on oral anticoagulants by addressing modifiable risk factors such as concomitant use of aspirin, which increases the hazard for major bleeding events by at least 50% [12].

In summary, to prevent further bleeding, physicians should ensure the following steps are taken in a patient resuming anticoagulant therapy:

- Preferentially prescribe DOACs with the lowest risk of GI bleeding rather than VKAs. The choice of DOAC cannot be determined by evidence-based medicine but should be determined by the risk of GI bleeding.
- Comply with all guidelines and prescribing information, especially avoiding DOAC accumulation related to kidney disease.
- Consider the effect of concomitant medications on potentiating the bleeding risk (e.g., CYP3A4 or P-gp inhibitors, antiplatelet agents) [93].
- Avoid medications with GI toxicity (nonsteroidal antiinflammatory drugs).
- Initiate treatment with PPIs to reduce the risk of bleeding (although be cognizant of a possible interaction between PPIs and dabigatran).
- Test patients with peptic ulcers for *Helicobacter pylori* and initiate eradication therapy as needed.

9 Conclusions

Guidelines now recommend DOACs over VKAs for the prevention of thromboembolism in patients with AF due to their safety and efficacy profiles. However, the major complication with DOAC treatment is the increased risk of bleeding, particularly GI bleeding. Management of GI

bleeding and resumption of oral anticoagulants in patients with AF are associated with increased survival rates. The optimal approach for patients with GI bleeding who are taking anticoagulants involves multidisciplinary care to provide an individualized optimal balance of benefit and risk for each patient.

Acknowledgements We would like to thank Catherine Rees and Alma Orts-Sebastien of Springer Healthcare Communications who wrote the outline and first draft, respectively. This medical writing assistance was funded by Pfizer and Bristol Myers Squibb.

Declarations

Conflicts of interest Anne-Céline Martin: BMS/Pfizer, Bayer, Boehringer Ingelheim, Astra Zeneca, Novartis. Robert Benamouzig: no relevant conflicts of interest to declare. Isabelle Gouin-Thibault: Alliance BMS/Pfizer, Bayer, Leo Pharma, Abbvie. Jeannot Schmidt: no relevant conflicts of interest to declare.

Funding Medical writing assistance was funded by Pfizer and Bristol Myers Squibb.

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Availability of data and material Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Code availability Not applicable.

Author contributions The content of this manuscript was originally based on discussions during expert meetings including all the authors. All authors critically reviewed the outline and first draft of the manuscript and have read and approved the final manuscript for submission.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

References

1. Bassand J-P, Apenteng PN, Atar D, Camm AJ, Cools F, Corbaltan R, et al. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. *Future Cardiol.* 2021;17(1):19–38. <https://doi.org/10.2217/fca-2020-0014>.

2. Dai H, Zhang Q, Much AA, Maor E, Segev A, Beinart R, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. *Eur Heart J Qual Care Clin Outcomes*. 2020;7(6):574–82. <https://doi.org/10.1093/ehjqcc/qcaa061>.
3. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Europace*. 2021;23(10):1612–76. <https://doi.org/10.1093/europace/euab065>.
4. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42(5):373–498. <https://doi.org/10.1093/eurheartj/ehaa612>.
5. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. *Drug Metab Dispos*. 2012;40(12):2250–5. <https://doi.org/10.1124/dmd.112.046888>.
6. Chan NC, Hirsh J, Ginsberg JS, Eikelboom JW. Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. *Future Cardiol*. 2014;10(1):43–52. <https://doi.org/10.2217/fca.13.98>.
7. Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. *Am J Health Syst Pharm*. 2008;65(16):1520–9. <https://doi.org/10.2146/ajhp070624>.
8. He K, Luettgen JM, Zhang D, He B, Grace JE, Xin B, et al. Pre-clinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. *Eur J Drug Metab Pharmacokinet*. 2011;36(3):129–39. <https://doi.org/10.1007/s13318-011-0037-x>.
9. Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated factor Xa. *Curr Opin Investig Drugs*. 2008;9(9):1020–33.
10. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. *Clin Appl Thromb Hemost*. 2009;15(Suppl 1):9s–16s. <https://doi.org/10.1177/1076029609343004>.
11. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37(38):2893–962. <https://doi.org/10.1093/eurheartj/ehw210>.
12. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2019;74(1):104–32. <https://doi.org/10.1016/j.jacc.2019.01.011>.
13. Cheung K-S, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. *World J Gastroenterol*. 2017;23(11):1954. <https://doi.org/10.3748/wjg.v23.i11.1954>.
14. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. *J Am Coll Cardiol*. 2020;76(5):594–622. <https://doi.org/10.1016/j.jacc.2020.04.053>.
15. Bouget J, Viglino D, Yvetot Q, Oger E. Major gastrointestinal bleeding and antithrombotics: characteristics and management. *World J Gastroenterol*. 2020;26(36):5463–73. <https://doi.org/10.3748/wjg.v26.i36.5463>.
16. Raymond J, Imbert L, Cousin T, Duflo T, Varin R, Wils J, et al. Pharmacogenetics of direct oral anticoagulants: a systematic review. *J Pers Med*. 2021;11(1):37. <https://doi.org/10.3390/jpm11010037>.
17. Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants in gastroenterology practice. *Gastrointest Endosc*. 2013;78(2):227–39. <https://doi.org/10.1016/j.gie.2013.04.179>.
18. Vaduganathan M, Bhatt DL. Gastrointestinal bleeding with oral anticoagulation: understanding the scope of the problem. *Clin Gastroenterol Hepatol*. 2017;15(5):691–3. <https://doi.org/10.1016/j.cgh.2016.12.033>.
19. Hellenbarth EL, Faulkenberg KD, Finks SW. Evaluation of bleeding in patients receiving direct oral anticoagulants. *Vasc Health Risk Manag*. 2017;13:325–42. <https://doi.org/10.2147/VHRM.S121661>.
20. Thapa N, Shatzel J, Deloughery TG, Olson SR. Direct oral anticoagulants in gastrointestinal malignancies: is the convenience worth the risk? *J Gastrointest Oncol*. 2019;10(4):807–9. <https://doi.org/10.21037/jgo.2019.02.07>.
21. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. *Circulation*. 2011;123(21):2363–72. <https://doi.org/10.1161/circulationaha.110.004747>.
22. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoagulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). *AM Heart J*. 2010;160(4):635–41.e2. <https://doi.org/10.1016/j.ahj.2010.06.042>.
23. Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh E-Y, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. *J Am Coll Cardiol*. 2015;66(21):2271–81. <https://doi.org/10.1016/j.jacc.2015.09.024>.
24. Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. *Am Heart J*. 2015;169(1):25–30. <https://doi.org/10.1016/j.ahj.2014.09.006>.
25. Cannon CP, Kohli P. Danger ahead: watch out for indirect comparisons! *J Am Coll Cardiol*. 2012;60(8):747–8. <https://doi.org/10.1016/j.jacc.2012.05.012>.
26. Desai JC, Chatterjee P, Friedman K, Aisenberg J. Incidence and clinical presentation of gastrointestinal bleeding in atrial fibrillation patients taking direct oral anticoagulants. *Am J Gastroenterol Suppl*. 2016;3(1):13. <https://doi.org/10.1038/ajgsup.2016.3>.
27. Sengupta N, Tapper EB, Patwardhan VR, Ketwaroo GA, Thaker AM, Leffler DA, et al. Risk factors for adverse outcomes in patients hospitalized with lower gastrointestinal bleeding. *Mayo Clin Proc*. 2015;90(8):1021–9. <https://doi.org/10.1016/j.mayocp.2015.04.024>.
28. Undas A, Drabik L, Potpara T. Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. *Kardiol Pol*. 2020;78(2):105–16. <https://doi.org/10.33963/KP.15205>.
29. White EM, Coons JC. Direct oral anticoagulant use in special populations: elderly, obesity, and renal failure. *Curr Cardiol Rep*. 2021;23(4):27. <https://doi.org/10.1007/s11886-021-01456-9>.

30. Gunasekaran K, Rajasurya V, Devasahayam J, Singh Rahi M, Chandran A, Elango K, et al. A review of the incidence diagnosis and treatment of spontaneous hemorrhage in patients treated with direct oral anticoagulants. *J Clin Med*. 2020;9(9):2984. <https://doi.org/10.3390/jcm9092984>.
31. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). *Am Heart J*. 2010;159(6):1102–7. <https://doi.org/10.1016/j.ahj.2010.03.027>.
32. Padrini R. Clinical pharmacokinetics and pharmacodynamics of direct oral anticoagulants in patients with renal failure. *Eur J Drug Metab Pharmacokinet*. 2019;44(1):1–12. <https://doi.org/10.1007/s13318-018-0501-y>.
33. Ha JT, Neuen BL, Cheng LP, Jun M, Toyama T, Gallagher MP, et al. Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis. *Ann Intern Med*. 2019;171(3):181–9. <https://doi.org/10.7326/m19-0087>.
34. Weinberg EM, Palecki J, Reddy KR. Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. *Semin Liver Dis*. 2019;39(2):195–208. <https://doi.org/10.1055/s-0039-1679934>.
35. Lobraico-Fernandez J, Baksh S, Nemeč E. Elderly bleeding risk of direct oral anticoagulants in nonvalvular atrial fibrillation: a systematic review and meta-analysis of cohort studies. *Drugs R D*. 2019;19(3):235–45. <https://doi.org/10.1007/s40268-019-0275-y>.
36. Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. *Gastroenterology*. 2017;152(5):1014–22. e1. <https://doi.org/10.1053/j.gastro.2016.12.018>.
37. Lip GYH. Implications of the CHA2DS2-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillation. *Am J Med*. 2011;124(2):111–4. <https://doi.org/10.1016/j.amjmed.2010.05.007>.
38. Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. *Thromb Haemost*. 2018;118(12):2171–87. <https://doi.org/10.1055/s-0038-1675400>.
39. Steinberg BA, Shrader P, Kim S, Thomas L, Fonarow GC, Ansell J, et al. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). *Am Heart J*. 2016;181:145–52. <https://doi.org/10.1016/j.ahj.2016.07.026>.
40. Srygley FD, Gerardo CJ, Tran T, Fisher DA. Does this patient have a severe upper gastrointestinal bleed? *JAMA*. 2012;307(10):1072–9. <https://doi.org/10.1001/jama.2012.253>.
41. Barnert J, Messmann H. Diagnosis and management of lower gastrointestinal bleeding. *Nat Rev Gastroenterol Hepatol*. 2009;6(11):637–46. <https://doi.org/10.1038/nrgastro.2009.167>.
42. Gralnek IM, Dumonceau J-M, Kuipers EJ, Lanas A, Sanders DS, Kurien M, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) guideline. *Endoscopy*. 2015;47(10):a1–46. <https://doi.org/10.1055/s-0034-1393172>.
43. Gaiani F, De'Angelis N, Kayali S, Manfredi M, Di Mario F, Leandro G, et al. Clinical approach to the patient with acute gastrointestinal bleeding. *Acta Biomed Ateneo Parmense*. 2018;89(8-S):12–9. <https://doi.org/10.23750/abm.v89i8-S.7861>.
44. Rodrigues A, Carrilho A, Almeida N, Baldaia C, Alves Á, Gomes M, et al. Interventional algorithm in gastrointestinal bleeding—an expert consensus multimodal approach based on a multidisciplinary team. *Clin Appl Thromb Hemost*. 2020;26:1076029620931943. <https://doi.org/10.1177/1076029620931943>.
45. McNulty PH, King N, Scott S, Hartman G, McCann J, Kozak M, et al. Effects of supplemental oxygen administration on coronary blood flow in patients undergoing cardiac catheterization. *Am J Physiol Heart Circ Physiol*. 2005;288(3):H1057–62. <https://doi.org/10.1152/ajpheart.00625.2004>.
46. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. *J Thromb Haemost*. 2010;8(1):202–4. <https://doi.org/10.1111/j.1538-7836.2009.03678.x>.
47. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost*. 2005;3(4):692–4. <https://doi.org/10.1111/j.1538-7836.2005.01204.x>.
48. Pernod G, Godier A, Gozalo C, Tremey B, Sie P. French National Authority for Health French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). *Thromb Res*. 2010;126(3):e167–74. <https://doi.org/10.1016/j.thromres.2010.06.017>.
49. Haute Autorité de Santé. Oral anticoagulants. Saint-Denis La Plaine. 2018. https://www.has-sante.fr/jcms/c_2851086/fr/les-anticoagulants-oraux. Accessed 22 July 2021.
50. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. *Lancet*. 2000;356(9238):1318–21. [https://doi.org/10.1016/S0140-6736\(00\)02816-6](https://doi.org/10.1016/S0140-6736(00)02816-6).
51. Piazza VM, Popenko NA, Winograd S. An evidence-based review of gastrointestinal bleeding evaluation and management in the emergency department. *Emerg Med Rep Relias Media*. 2019. <https://www.reliasmedia.com/articles/144557-an-evidence-based-review-of-gastrointestinal-bleeding-evaluation-and-management-in-the-emergency-department>. Accessed 27 Apr 2021.
52. Jung K, Moon W. Role of endoscopy in acute gastrointestinal bleeding in real clinical practice: an evidence-based review. *World J Gastrointest Endosc*. 2019;11(2):68–83. <https://doi.org/10.4253/wjge.v11.i2.68>.
53. U.S. Food and Drug Administration. SAVAYSA™ (edoxaban) prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206316s0151bl.pdf. Accessed 2 Aug 2021.
54. U.S. Food and Drug Administration. PRADAXA® (dabigatran etexilate) prescribing information. 2021. <https://docs.boehringer-ingenelheim.com/Prescribing%20Information/Pis/Pradaxa/Pradaxa.pdf>. Accessed 4 Aug 2021.
55. U.S. Food and Drug Administration. XARELTO (rivaroxaban) prescribing information. 2021. <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf>. Accessed 4 Aug 2021.
56. U.S. Food and Drug Administration. ELIQUIS® (apixaban) prescribing information. 2021. https://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed 4 Aug 2021.
57. Chen A, Stecker E, Bruce AW. Direct oral anticoagulant use: a practical guide to common clinical challenges. *J Am Heart Assoc*. 2020;9(13):e017559. <https://doi.org/10.1161/jaha.120.017559>.
58. Ur-Rahman A, Guan J, Khalid S, Munaf A, Sharbatji M, Idrisov E, et al. Both full Glasgow–Blatchford score and modified Glasgow–Blatchford score predict the need for intervention and mortality in patients with acute lower gastrointestinal bleeding. *Dig Dis Sci*. 2018;63(11):3020–5. <https://doi.org/10.1007/s10620-018-5203-4>.

59. Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. *Lancet*. 1974;2(7877):394–7. [https://doi.org/10.1016/s0140-6736\(74\)91770-x](https://doi.org/10.1016/s0140-6736(74)91770-x).
60. Lee S, Ahn JY, Jung HY, Jung KW, Lee JH, Kim DH, et al. Effective endoscopic treatment of Mallory-Weiss syndrome using Glasgow-Blatchford score and Forrest classification. *J Dig Dis*. 2016;17(10):676–84. <https://doi.org/10.1111/1751-2980.12409>.
61. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. *Gut*. 1996;38(3):316–21. <https://doi.org/10.1136/gut.38.3.316>.
62. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. *Ann Intern Med*. 2010;152(2):101–13. <https://doi.org/10.7326/0003-4819-152-2-201001190-00009>.
63. Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. *Am J Gastroenterol*. 2016;111(4):459–74. <https://doi.org/10.1038/ajg.2016.41>.
64. Pasha SF, Shergill A, Acosta RD, Chandrasekhara V, Chathadi KV, Early D, et al. The role of endoscopy in the patient with lower GI bleeding. *Gastrointest Endosc*. 2014;79(6):875–85. <https://doi.org/10.1016/j.gie.2013.10.039>.
65. Conway JD, Adler DG, Diehl DL, Farraye FA, Kantsevov SV, Kaul V, et al. Endoscopic hemostatic devices. *Gastrointest Endosc*. 2009;69(6):987–96. <https://doi.org/10.1016/j.gie.2008.12.251>.
66. Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, et al. Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. *Am J Hematol*. 2019;94(6):697–709. <https://doi.org/10.1002/ajh.25475>.
67. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2016;14(3):623–7. <https://doi.org/10.1111/jth.13227>.
68. U.S. Food and Drug Administration. PRAXBIND® (idarucizumab) prescribing information. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf. Accessed 2 Aug 2021.
69. Marano G, Vaglio S, Pupella S, Liembruno GM, Franchini M. How we treat bleeding associated with direct oral anticoagulants. *Blood Transfus*. 2016;14(5):465–73. <https://doi.org/10.2450/2016.0180-15>.
70. Sheikh-Taha M. Idarucizumab for reversal of dabigatran: single-center real-world experience. *Am J Cardiovasc Drugs*. 2019;19(1):59–64. <https://doi.org/10.1007/s40256-018-0300-5>.
71. Chaudhary R, Sharma T, Garg J, Sukhi A, Bliden K, Tantry U, et al. Direct oral anticoagulants: a review on the current role and scope of reversal agents. *J Thromb Thrombolysis*. 2020;49(2):271–86. <https://doi.org/10.1007/s11239-019-01954-2>.
72. U.S. Food and Drug Administration. ANDEXXA® (coagulation factor Xa) prescribing information. 2018. <https://www.fda.gov/media/113279/download>. Accessed 02 Aug 2021.
73. Sheikh-Taha M, Crawley RM. Reversal of apixaban and rivaroxaban using activated prothrombin complex concentrates in patients with major bleeding. *Am J Cardiovasc Drugs*. 2020;20(3):295–9. <https://doi.org/10.1007/s40256-019-00383-z>.
74. Sengupta N, Feuerstein JD, Patwardhan VR, Tapper EB, Ketwaroo GA, Thaker AM, et al. The risks of thromboembolism vs recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. *Am J Gastroenterol*. 2015. <https://doi.org/10.1038/ajg.2014.398>.
75. Proietti M, Romiti GF, Romanazzi I, Farcomeni A, Staerk L, Nielsen PB, et al. Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: a systematic review and meta-analysis. *Int J Cardiol*. 2018;261:84–91. <https://doi.org/10.1016/j.ijcard.2018.03.053>.
76. Little D, Chai-Adisaksotha C, Hillis C, Witt DM, Monreal M, Crowther MA, et al. Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis. *Thromb Res*. 2019;175:102–9. <https://doi.org/10.1016/j.thromres.2019.01.020>.
77. Tapaskar N, Pang A, Werner DA, Sengupta N. Resuming anticoagulation following hospitalization for gastrointestinal bleeding is associated with reduced thromboembolic events and improved mortality: results from a systematic review and meta-analysis. *Dig Dis Sci*. 2021;66(2):554–66. <https://doi.org/10.1007/s10620-020-06248-9>.
78. Kido K, Scalese MJ. Management of oral anticoagulation therapy after gastrointestinal bleeding: whether to, when to, and how to restart an anticoagulation therapy. *Ann Pharmacother*. 2017;51(11):1000–7. <https://doi.org/10.1177/1060028017717019>.
79. Radaelli F, Fuccio L, Paggi S, Bono CD, Dumonceau JM, Dentali F. What gastroenterologists should know about direct oral anticoagulants. *Dig Liver Dis*. 2020;52(10):1115–25. <https://doi.org/10.1016/j.dld.2020.04.032>.
80. Witt DM. What to do after the bleed: resuming anticoagulation after major bleeding. *Hematology*. 2016;2016(1):620–4. <https://doi.org/10.1182/asheducation-2016.1.620>.
81. Albaladejo P, Pernod G, Godier A, de Maistre E, Rosencher N, Mas JL, et al. Management of bleeding and emergency invasive procedures in patients on dabigatran: updated guidelines from the French Working Group on perioperative haemostasis (GIHP)—September 2016. *Anaesth Crit Care Pain Med*. 2018;37(4):391–9. <https://doi.org/10.1016/j.accpm.2018.04.009>.
82. Majeed A, Wallvik N, Eriksson J, Höijer J, Bottai M, Holmström M, et al. Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding: a risk modelling analysis. *Thromb Haemost*. 2017;117(3):491–9. <https://doi.org/10.1160/TH16-07-0498>.
83. Qureshi W, Mittal C, Patsias I, Garikapati K, Kuchipudi A, Cheema G, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. *Am J Cardiol*. 2014;113(4):662–8. <https://doi.org/10.1016/j.amjcard.2013.10.044>.
84. Witt DM, Delate T, Garcia DA, Clark NP, Hylek EM, Ageno W, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. *Arch Intern Med*. 2012;172(19):1484–91. <https://doi.org/10.1001/archinternmed.2012.4261>.
85. Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. *Eur Heart J*. 2015;36(20):1264–72. <https://doi.org/10.1093/eurheartj/ehu463>.
86. Van der Wall SJ, Lopes RD, Aisenberg J, Reilly P, van Ryn J, Glund S, et al. Idarucizumab for dabigatran reversal in the management of patients with gastrointestinal bleeding. *Circulation*. 2019;139(6):748–56. <https://doi.org/10.1161/CIRCULATIONAHA.118.036710>.
87. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. *Europace*. 2018;20(8):1231–42. <https://doi.org/10.1093/europace/euy054>.
88. Pipilis A, Makrygiannis S, Chrisanthopoulou E, Sourlas N, Kaliambakos S, Ntalianas P. Gastrointestinal bleeding in patients receiving antiplatelet and anticoagulant therapy: practical

- guidance for restarting therapy and avoiding recurrences. *Hellenic J Cardiol.* 2014;55(6):499–509.
89. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet.* 2014;383(9921):955–62. [https://doi.org/10.1016/S0140-6736\(13\)62343-0](https://doi.org/10.1016/S0140-6736(13)62343-0).
 90. Lip GYH, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, et al. Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding. *JAMA Netw Open.* 2021;4(8):e2120064. <https://doi.org/10.1001/jamanetworkopen.2021.20064>.
 91. Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, et al. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. *JAMA.* 2021;326(23):2395–404. <https://doi.org/10.1001/jama.2021.21222>.
 92. Souverein PC, van den Ham HA, Huerta C, Merino EM, Montero D, León-Muñoz LM, et al. Comparing risk of major bleeding between users of different oral anticoagulants in patients with non-valvular atrial fibrillation. *Br J Clin Pharmacol.* 2021;87(3):988–1000. <https://doi.org/10.1111/bcp.14450>.
 93. Sheikh-Taha M, Deeb ME. Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA: a chart review of 909 patients. *Am J Cardiovasc Drugs.* 2019;19(2):195–201. <https://doi.org/10.1007/s40256-018-0310-3>.